AKARI Therapeutics Company

Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.
Technology: Scientifically-Validated Lifestyle Recommendation
Industry: Stem Cell Exhaustion
Headquarters: United States
Founded Date: 2005
Employees Number: 11-50
Funding Status: IPO

Visit Website
IR@akaritx.com
Register and Claim Ownership